In the claims:

This listing of claims will replace all prior versions and listings of the claims in the application:

Claims 1-44 (canceled)

45. (currently amended) A composition comprising ambroxol or its salts ~~or prodrugs~~ and at least one inhibitor of the angiotension-converting enzyme.

46. (previously presented) The composition according to claim 45, additionally comprising α-lipoic acid or its salts or its isomers.

47. (previously presented) The composition according of claim 45, further comprising pharmaceutically acceptable carriers, additives and/or adjuvants.

48. (previously presented) The composition of claim 45, wherein the ambroxol and/or its salts are in amounts of from 7.5 to 90 mg.

49. (previously presented) The composition of claim 48, wherein the ambroxol and/or its salts are in amounts of from 60 to 75 mg.

50. (previously presented) The composition of claim 45, wherein the inhibitor of the angiotension-converting enzyme is in an amount of from 1 to 50 mg.

51. (previously presented) The composition of claim 50, wherein the inhibitor of the angiotension-converting enzyme is in an amount of from 5 to 20 mg.

52. (previously presented) The composition of claim 46, wherein the α-lipoic acid or its salts or its isomers are in an amount of from 30 to 1,200 mg.

53. (previously presented) The composition of claim 52, wherein the α-lipoic acid or its salts or its isomers are present in the range of from 200 to 600 mg.

54. (previously presented) The composition of claim 45, wherein the inhibitor of angiotension-converting enzyme is selected from the group consisting of captopril, lisinopril, enalapril, ramipril, spirapril, imidapril and moexipril.

55. (currently amended) A method for preventing a neurodegenerative disease or ischemia comprising administering to an individual an effective amount of a composition comprising comprising ambroxol or its salts ~~or prodrugs~~ and at least one inhibitor of the angiotension-converting enzyme.

56. (previously presented) The method according to claim 55, wherein the neurodegenerative disease is selected from the group consisting of ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus.

57. (previously presented) The method of claim 55, wherein the ischemia is cerebral ischemia resulting from cardiac and cardiovascular insults.

58. (previously presented) The method of claim 55, wherein the composition further comprises α-lipoic acid or its salts or its isomers.

59. (previously presented) The method of claim 55, wherein the composition further comprises pharmaceutically acceptable carriers, additives and/or adjuvants.

60. (currently amended) The method of claim 58, wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 30 to 1,200 mg/day, and/or ambroxol or its salts ~~or its prodrugs~~ are administered in an amount of from 7.5 to 90 mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 1 to 50 mg/day.

61. (currently amended) The method of claim 60, wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 200 to 600 mg/day, and/or ambroxol or its salts ~~or its prodrugs~~ are administered in an amount of from 60 to 75

mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 5 to 20 mg/day.

62. (previously presented) The method of claim 55, wherein the composition is administered by a route selected from buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

63. (previously presented) The method of claim 55, wherein the composition is administered in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

64. (previously presented) A composition comprising ambroxol or its salts and at least one inhibitor of the angiotension-converting enzyme.

65. (previously presented) The composition of claim 64, further comprising α-lipoic acid or its salts or its isomers.

66. (previously presented) The composition according of claim 64, further comprising pharmaceutically acceptable carriers, additives and/or adjuvants.

67. (currently amended) The composition of claim 64, wherein the ambroxol and its salts ~~or prodrugs~~ are in amounts of from 7.5 to 90 mg.

68. (currently amended) The composition of claim 67, wherein the ambroxol and its salts ~~or prodrugs~~ are in amounts of from 60 to 75 mg.

69. (previously presented) The composition of claim 64, wherein the inhibitor of the angiotension-converting enzyme is in an amount of from 1 to 50 mg.

70. (previously presented) The composition of claim 69, wherein the inhibitor of the angiotension-converting enzyme is in an amount of from 5 to 20 mg.

71. (previously presented) The composition of claim 65, wherein the α-lipoic acid or its salts or its isomers are in an amount of from 30 to 1,200 mg.

72. (previously presented) The composition of claim 71, wherein the α-lipoic acid or its salts or its isomers are present in the range of from 200 to 600 mg/d.

73. (previously presented) The composition of claim 64, wherein the composition is in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

74. (previously presented) A method for preventing a neurodegenerative disease or ischemia comprising administering to an individual an effective amount of a composition comprising comprising ambroxol or its salts and at least one inhibitor of the angiotension-converting enzyme.

75. (previously presented) The method according to claim 74, wherein the neurodegenerative disease is selected from the group consisting of ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus.

76. (previously presented) The method of claim 74, wherein the ischemia is cerebral ischemia resulting from cardiac and cardiovascular insults.

77. (previously presented) The method of claim 74, wherein the composition further comprises α-lipoic acid or its salts or its isomers.

78. (previously presented) The method of claim 74, wherein the composition further comprises pharmaceutically acceptable carriers, additives and/or adjuvants.

79. (currently amended) The method of claim 77, wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 30 to 1,200 mg/day, and/or ambroxol or its salts ~~or its prodrugs~~ are administered in an amount of from 7.5 to 90

mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 1 to 50 mg/day.

80. (currently amended) The method of claim 79, wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 200 to 600 mg/day, and/or ambroxol or its salts ~~or its prodrugs~~ are administered in an amount of from 60 to 75 mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 5 to 20 mg/day.

81. (previously presented) The method of claim 74, wherein the composition is administered by a route selected from buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

82. (previously presented) A composition comprising ambroxol, at least one inhibitor of the angiotensin-converting enzyme, and α-lipoic acid, wherein the composition is capable of syngergistically enhancing the survival of neurons after oxygen and/or glucose deprivation.

83. (previously presented) A method for obtaining a synergistic improvement in the survival of neuronal cells after oxygen and/or glucose deprivation in an individual comprising administering to the individual a composition comprising ambroxol, at least one inhibitor of the angiotensin-converting enzyme, and α-lipoic acid.

84. (previously presented) The method of claim 83, wherein the inhibitor of the angiotensin-converting enzyme is selected from the group consisting of captopril, lisinopril, enalapril, ramipril, spirapril, imidapril and moexipril.

85. (previously presented) The method of claim 84, wherein the angiotensin-converting enzyme is elanapril.

86. (currently amended) The method of claim ~~82~~ 83, wherein the composition further comprises a pharmaceutically acceptable carrier.